Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from OneSource Specialty Pharma Limited ( (IN:ONESOURCE) ).
OneSource Specialty Pharma Limited said partner Dr. Reddy’s Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of diabetes and weight-loss drug Ozempic. OneSource serves as the CDMO on the program, providing scale-up and commercial manufacturing from its US FDA-approved flagship facility in Bengaluru, reinforcing the partners’ capabilities in complex peptide injectables and supporting reliable supply to the Canadian market.
Management said the approval deepens OneSource’s collaboration with Dr. Reddy’s by combining the latter’s peptide development expertise with OneSource’s manufacturing strengths. The deal underscores OneSource’s role in the high-growth market for GLP-1 therapies and highlights its strategy to leverage its regulatory-compliant capacity to attract more global specialty pharma partnerships.
More about OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited is a pure-play specialty pharmaceutical contract development and manufacturing organization focused on complex products such as biologics, drug-device combinations, sterile injectables and oral technologies like soft gelatin capsules. The company operates five globally approved manufacturing facilities, employs over 1,600 professionals, and targets global pharma clients seeking end-to-end, compliant development and commercial manufacturing solutions.
Average Trading Volume: 54,197
Technical Sentiment Signal: Buy
Current Market Cap: 208B INR
Learn more about ONESOURCE stock on TipRanks’ Stock Analysis page.